These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9202333)

  • 1. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide.
    Webster S; Bradt B; Rogers J; Cooper N
    J Neurochem; 1997 Jul; 69(1):388-98. PubMed ID: 9202333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide.
    Emmerling MR; Spiegel K; Watson MD
    Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
    Cottingham MG; Hollinshead MS; Vaux DJ
    Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation by the amyloid proteins A beta peptide and beta 2-microglobulin.
    Nybo M; Nielsen EH; Svehag SE
    Amyloid; 1999 Dec; 6(4):265-72. PubMed ID: 10611947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.
    Bergamaschini L; Canziani S; Bottasso B; Cugno M; Braidotti P; Agostoni A
    Clin Exp Immunol; 1999 Mar; 115(3):526-33. PubMed ID: 10193429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation.
    Hughes E; Burke RM; Doig AJ
    J Biol Chem; 2000 Aug; 275(33):25109-15. PubMed ID: 10825171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of complement and contact system in Alzheimer's disease.
    Bergamaschini L; Donarini C; Gobbo G; Parnetti L; Gallai V
    Mech Ageing Dev; 2001 Nov; 122(16):1971-83. PubMed ID: 11589915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement activation by cross-linked truncated and chimeric full-length beta-amyloid.
    Cribbs DH; Velazquez P; Soreghan B; Glabe CG; Tenner AJ
    Neuroreport; 1997 Nov; 8(16):3457-62. PubMed ID: 9427307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis.
    Velazquez P; Cribbs DH; Poulos TL; Tenner AJ
    Nat Med; 1997 Jan; 3(1):77-9. PubMed ID: 8986745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide.
    Bradt BM; Kolb WP; Cooper NR
    J Exp Med; 1998 Aug; 188(3):431-8. PubMed ID: 9687521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide.
    Shen Y; Sullivan T; Lee CM; Meri S; Shiosaki K; Lin CW
    Brain Res; 1998 Jun; 796(1-2):187-97. PubMed ID: 9689469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
    Webster SD; Tenner AJ; Poulos TL; Cribbs DH
    Neurobiol Aging; 1999; 20(3):297-304. PubMed ID: 10588577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common benzothiazole and benzoxazole fluorescent DNA intercalators for studying Alzheimer Aβ1-42 and prion amyloid peptides.
    Stefansson S; Adams DL; Tang CM
    Biotechniques; 2012 May; 52(5):. PubMed ID: 26307253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physico-chemical methods for studing β-amyloid aggregation].
    Radko SP; Khmeleva SA; Suprun EV; Kozin SA; Bodoev NV; Makarov AA; Archakov AI; Shumyantseva VV
    Biomed Khim; 2015; 61(2):203-18. PubMed ID: 25978387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches.
    Chen S; Frederickson RC; Brunden KR
    Neurobiol Aging; 1996; 17(5):781-7. PubMed ID: 8892352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.
    Brubaker WD; Crane A; Johansson JU; Yen K; Garfinkel K; Mastroeni D; Asok P; Bradt B; Sabbagh M; Wallace TL; Glavis-Bloom C; Tenner AJ; Rogers J
    Alzheimers Dement; 2017 Dec; 13(12):1397-1409. PubMed ID: 28475854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology.
    Styren SD; Hamilton RL; Styren GC; Klunk WE
    J Histochem Cytochem; 2000 Sep; 48(9):1223-32. PubMed ID: 10950879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta-amyloid protein activation of complement in vitro.
    McGeer PL; Walker DG; Pitas RE; Mahley RW; McGeer EG
    Brain Res; 1997 Feb; 749(1):135-8. PubMed ID: 9070638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles.
    Hook VY; Toneff T; Aaron W; Yasothornsrikul S; Bundey R; Reisine T
    J Neurochem; 2002 Apr; 81(2):237-56. PubMed ID: 12064471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Charged surfactants induce a non-fibrillar aggregation pathway of amyloid-beta peptide.
    Loureiro JA; Rocha S; Pereira Mdo C
    J Pept Sci; 2013 Sep; 19(9):581-7. PubMed ID: 23922329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.